comparemela.com

(Bloomberg) -- Roche Holding AG agreed to pay as much as $3.1 billion for Carmot Therapeutics Inc., a developer of the new type of weight-loss treatments that’s sparked a pharma industry gold rush.Most Read from BloombergHow Suspects Laundered Billions in Singapore for YearsBonds Retreat as Doubts Over Rate Cuts Creep In: Markets WrapBitcoin Surges Past $42,000 as Crypto Rally Gathers SteamHere’s How to Invest in Gold as It Hits an All-Time HighAlaska Air Agrees to Buy Hawaiian in $1.9 Billion D

Related Keywords

Switzerland ,Hong Kong ,Zurich ,Züsz ,Berkeley ,California ,United States ,Denmark ,China ,Danish ,Swiss ,Chinese ,Shirley Zhao ,Bloomberg Businessweek ,Novo Nordisk ,Li Ka Shing ,Eli Lilly ,Astrazeneca Plc ,Bloomberg Roche Holding ,Column Group ,Telavant Holdings Inc ,Pfizer Inc ,Carmot Therapeutics Inc ,Eli Lilly Co ,Bloomberg ,Weight Loss Drugmaker Carmot Therapeutics Is Said ,Horizons Ventures ,Bloomberg Billionaires ,California Based Carmot ,Roche Holding Ag ,Experimental Medicine ,Weight Loss ,Drug Developer ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.